Sofosbuvir and ABT-450: Terminator of hepatitis C virus?

Table 6 Outcome of representative direct acting antiviral agent-based therapy for genotype 1 null responders

Authors	n	Therapeutic schedule	SVR rate
Zeuzem et al[32]	37	(pegIFN-α2a + RBV) 4 wk + (pegIFN-α2a + RBV + telaprevir) 12 wk + (pegIFN-α2a + RBV) 32 wk	33%
Bacon et al[33]	58	(pegIFN-α2b + RBV) 4 wk + (pegIFN-α2b + RBV + boceprevir) 44 wk	52%
Lok et al[36]	11	Daclatasvir + asunaprevir 24 wk	36%
Lok et al[36]	10	Daclatasvir + asunaprevir + pegIFN-α2a + RBV 24 wk	90%
Gane et al[37]	10	Sofosbuvir + RBV 12 wk	10%
Poordad et al[38]	7	ABT-450 + ritonavir + ABT-333 + RBV 12wk	43%

pegIFN-α: Peginterferon-α; SVR: Sustained virologic response; RBV: Ribavirin.